ArticleClinical toxicology (Philadelphia, Pa.)2026
Characterizing pediatric xylazine exposures reported to United States poison centers, 2010-2024.
Article in Clinical toxicology (Philadelphia, Pa.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionXylazine is an alpha-2 adrenergic receptor agonist not approved for use in humans. Xylazine has been increasingly found in the United States illegal drug supply and has been detected in fentanyl-associated overdose deaths. There are limited data on xylazine exposures in the pediatric population.
methodsData were obtained from America's Poison Centers® National Poison Data System® (NPDS), a near real-time surveillance system that collects data from poison centers across the US. A retrospective descriptive analysis was performed for xylazine-associated exposures reported to National Poison Data System® from January 2010 to December 2024 in children and teenagers ages 0-19 years.
resultsThere were 109 xylazine-associated exposures. Exposures increased over time, with most occurring during 2022-2024. The age distribution of xylazine-associated exposures included 57 (52.3%) among ages 0-5 years, four (3.7%) among ages 6-12 years, and 48 (44.0%) among ages 13-19 years. Thirty-six (33.0%) exposures were coded as xylazine only and 73 (67.0%) as xylazine plus at least one co-occurring substance. The most commonly coded co-exposure was fentanyl 55 (50.5%). Among exposures to xylazine only, the most common clinical effects were central nervous system (CNS) depression 15 (41.7%) and bradycardia four (11.1%). Among exposures to xylazine plus fentanyl, the most common clinical effects were CNS depression 44 (80.0%) and respiratory depression 38 (69.1%). Six patients died, all in the setting of xylazine co-occurring with fentanyl. DISCUSSION: In the pediatric population, the clinical effects of exposure to xylazine only are grossly similar to those of other alpha-2 agonists. Contrary to exposures in adults, the medical sequelae of fentanyl exposure may be worsened by xylazine co-exposure in some pediatric populations. The limitations of this study are discussed.
conclusionsBased on National Poison Data System® data, pediatric xylazine-related exposures are relatively uncommon. Clinicians must remain vigilant for adulterants, including the possible re-emergence of xylazine, in the illegal drug supply.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.